Todd Engel experienced vision loss, initially diagnosed as **NAION**, following the use of Ozempic, a **GLP-1** medication for diabetes. Legal action alleges Novo Nordisk failed to adequately warn patients and doctors about the potential risk of **NAION**.
Ongoing lawsuits involve numerous plaintiffs reporting harm from **GLP-1** drugs, with over 1,000 reports of optic neuropathy submitted to the FDA’s adverse event database since 2024. The FDA’s database contains nearly 190,000 reports overall, primarily concerning gastrointestinal issues and injection site reactions.
Research by JAMA Ophthalmology showed a correlation between Ozempic/semaglutide use and NAION, but medical groups cautioned against definitive causation. The FDA is conducting its own study on NAION risks and assessing claims, while drugmakers maintain rare side effects in clinical trials.
Over 1,928 reports of pancreatitis have been logged with the FDA since 2024, alongside reports of other serious digestive conditions. Plaintiffs argue for updated warnings, citing the inability to detect rare events in clinical trials and the need for diverse patient populations.
Concerns exist regarding online drug sales and the lack of medical supervision, leading to increased calls to poison control centers. The complexity of metabolic diseases and potential underlying conditions complicate attributing side effects solely to GLP-1 medications.
Legal challenges seek damages and improved warning labels, while Engel mourns the loss of his ability to perform activities he previously enjoyed.